Article Text

PDF
Phenotype and genotype in mucolipidoses II and III alpha/beta: a study of 61 probands
  1. S S Cathey1,
  2. J G Leroy1,
  3. T Wood1,
  4. K Eaves1,
  5. R J Simensen1,
  6. M Kudo2,
  7. R E Stevenson1,
  8. M J Friez1
  1. 1Greenwood Genetic Center, Greenwood, South Carolina, USA
  2. 2Genzyme Corporation, Oklahoma City, Oklahoma, USA
  1. Correspondence to Dr S S Cathey, Greenwood Genetic Center, Charleston Office, Montague Oaks Office Park, 3520 W Montague Avenue, Suite 104, N Charleston, SC 29418, USA; scathey{at}ggc.org

Abstract

Background Mucolipidoses II and III alpha/beta (ML II and ML III) are lysosomal disorders in which the essential mannose 6-phosphate recognition marker is not synthesised on to lysosomal hydrolases and other glycoproteins. The disorders are caused by mutations in GNPTAB, which encodes two of three subunits of the heterohexameric enzyme, N-acetylglucosamine-1-phosphotransferase.

Objectives Clinical, biochemical and molecular findings in 61 probands (63 patients) are presented to provide a broad perspective of these mucolipidoses.

Methods GNPTAB was sequenced in all probands and/or parents. The activity of several lysosomal enzymes was measured in plasma, and GlcNAc-1-phosphotransferase was assayed in leucocytes. Thirty-six patients were studied in detail, allowing extensive clinical data to be abstracted.

Results ML II correlates with near-total absence of phosphotransferase activity resulting from homozygosity or compound heterozygosity for frameshift or nonsense mutations. Craniofacial and orthopaedic manifestations are evident at birth, skeletal findings become more obvious within the first year, and growth is severely impaired. Speech, ambulation and cognitive function are impaired. ML III retains a low level of phosphotransferase activity because of at least one missense or splice site mutation. The phenotype is milder, with minimal delays in milestones, the appearance of facial coarsening by early school age, and slowing of growth after the age of 4 years.

Conclusions Fifty-one pathogenic changes in GNPTAB are presented, including 42 novel mutations. Ample clinical information improves criteria for delineation of ML II and ML III. Phenotype–genotype correlations suggested in more general terms in earlier reports on smaller groups of patients are specified and extended.

Statistics from Altmetric.com

Footnotes

  • An additional table is published online at http://jmg.bmj.com/content/vol47/issue1

  • Competing interests None.

  • Patient consent Obtained.

  • Provenance and Peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.